Refine
Document Type
- Article (2)
Language
- English (2) (remove)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2) (remove)
Keywords
- Sterblichkeit (2) (remove)
Institute
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome.
Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death.
Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined with achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend).
Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low.
Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402.
Both, G. mellonella and S. exigua, are most important pests in tropical countries. G. mellonella has five to six generations per year (Abid et al. 1997; Ali 1996), there, and feeding in bee combs they find, besides wax, residues of honey, insect skin and pollen (Hachiro & Knox 2000). Li et al. (1987) have shown the efficacy of Bacillus thuringiensis aizawai against G. mellonella. It is registered in the EU as Mellonex for its control, but NeemAzal T/S may also be active, and will have some advantages (Leymann et al. 2000, Melathopoulos et al. 2000). Therefore we conducted new studies here, on the results we shall report. S. exigua is an important polyphagous pest of crops in tropical areas (Brown & Dewhurst 1975). By repeated control with synthetic insecticides, especially by illiterate farmers (Armes et al. 1992; Aggarwal et al. 2006a) resistance to a lot of those insecticides has been built up, making plant protection very difficult. Therefore the need is pronounced for microbial and botanical pesticides (Nagarkatti 1982; Rao et al. 1990), which have different modes of action than synthetic insecticides. Aggarwal et al. (2006b) have started to test such ingredients, but the time of observation was too short (3 days), since the effects of Neem products occur later than those of synthetic insecticides (Basedow et al. 2002). So we conducted new, longer lasting experiments (with 5 to 30 days), on which we give a report here. The experiments were conducted during guest stays of the three co-authors (from Mymensingh, Bangladesh, from Nazreth, Ethiopia, and from Khartoum, Sudan) at the Experimental Station of the Institute of Phytopathology and Applied Zoology at Giessen Univerity.